Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cognition Therapeutics, Inc

0.4574
-0.0324-6.61%
Volume:627.71K
Turnover:295.35K
Market Cap:28.35M
PE:-0.48
High:0.5000
Open:0.5000
Low:0.4518
Close:0.4898
Loading ...

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

GlobeNewswire
·
20 Feb

B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating

MT Newswires Live
·
06 Feb

Cognition Therapeutics price target raised to $2 from $1.50 at B. Riley

TIPRANKS
·
06 Feb

Director Makes Bold Move with Major Stock Purchase in Cognition Therapeutics

TIPRANKS
·
05 Feb

Cognition’s Positive Phase 2 ‘Shimmer’ Study of Zervimesine (Ct1812) in Dementia With Lewy Bodies (Dlb) Will Be Presented in a Podium Presentation at Ilbdc

THOMSON REUTERS
·
30 Jan

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

GlobeNewswire
·
30 Jan

Cognition Therapeutics Shows Promising Phase 2 Study Results

TIPRANKS
·
14 Jan

Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

ACCESSWIRE
·
10 Jan

B. Riley Upgrades Cognition Therapeutics to Buy From Neutral, Lifts PT to $1.50 From $1

MT Newswires Live
·
19 Dec 2024

B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data

TIPRANKS
·
19 Dec 2024

Cognition Therapeutics upgraded to Buy from Neutral at B. Riley

TIPRANKS
·
19 Dec 2024

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires Live
·
19 Dec 2024

Cognition Therapeutics Shares More Than Double as Dementia Drug Meets Main Goal in Mid-Stage Trial

THOMSON REUTERS
·
18 Dec 2024

Cognition Therapeutics Says Study of Drug to Treat Lewy Body Dementia Meets Primary Endpoint; Shares Jump

MT Newswires Live
·
18 Dec 2024

BUZZ-Cognition Therapeutics rises as dementia drug meets main goal in mid-stage trial

Reuters
·
18 Dec 2024

Cognition Therapeutics Shares up 62.7% Premarket After Dementia Drug Meets Main Goal in Mid-Stage Trial

THOMSON REUTERS
·
18 Dec 2024